CureVac NV
NASDAQ:CVAC

Watchlist Manager
CureVac NV Logo
CureVac NV
NASDAQ:CVAC
Watchlist
Price: 2.99 USD 1.01%
Market Cap: 670.7m USD
Have any thoughts about
CureVac NV?
Write Note

CureVac NV
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CureVac NV
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
CureVac NV
NASDAQ:CVAC
Total Current Liabilities
€186.4m
CAGR 3-Years
-9%
CAGR 5-Years
46%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Total Current Liabilities
€2.1B
CAGR 3-Years
51%
CAGR 5-Years
75%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Total Current Liabilities
€487.8m
CAGR 3-Years
34%
CAGR 5-Years
59%
CAGR 10-Years
31%
Immatics NV
NASDAQ:IMTX
Total Current Liabilities
€156.6m
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Total Current Liabilities
€277.1m
CAGR 3-Years
39%
CAGR 5-Years
22%
CAGR 10-Years
8%
Formycon AG
XETRA:FYB
Total Current Liabilities
€69.3m
CAGR 3-Years
107%
CAGR 5-Years
65%
CAGR 10-Years
N/A
No Stocks Found

CureVac NV
Glance View

Market Cap
670.8m USD
Industry
Biotechnology

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

CVAC Intrinsic Value
4.32 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

What is CureVac NV's Total Current Liabilities?
Total Current Liabilities
186.4m EUR

Based on the financial report for Dec 31, 2023, CureVac NV's Total Current Liabilities amounts to 186.4m EUR.

What is CureVac NV's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
46%

Over the last year, the Total Current Liabilities growth was 19%. The average annual Total Current Liabilities growth rates for CureVac NV have been -9% over the past three years , 46% over the past five years .

Back to Top